Key Highlights
- Incyte acquires Escient Pharmaceuticals for $750 million plus net cash.
- Acquisition includes EP262 and EP547, first-in-class MRGPR antagonists.
- Enhances Incyte’s Inflammation and Autoimmunity portfolio.
- Potential treatments for mast cell-mediated diseases and severe pruritus.
Source: Business Wire
Notable Quotes
- “The acquisition of Escient and its first-in-class oral MRGPR antagonists bolsters our Inflammation and Autoimmunity portfolio and our commitment to creating innovative solutions that address the urgent needs of patients living with severe inflammatory diseases.” – Hervé Hoppenot, Chief Executive Officer at Incyte
- “Over the past six years, Escient has pioneered the characterization of MRGPR biology and advanced two novel candidates, EP262 and EP547, into clinical development.” – Joshua Grass, Chief Executive Officer at Escient Pharmaceuticals
SoHC's Take
Incyte’s strategic acquisition of Escient Pharmaceuticals marks a significant expansion of its therapeutic portfolio, particularly in the field of inflammation and autoimmunity. The inclusion of EP262 and EP547, both first-in-class MRGPR antagonists, positions Incyte at the forefront of developing treatments for a range of mast cell-mediated and pruritic conditions. This move not only underscores Incyte’s commitment to addressing unmet medical needs but also enhances its capability to innovate and accelerate the development of groundbreaking therapies. The expertise and pioneering work of Escient in MRGPR biology will be a valuable addition to Incyte’s ongoing efforts to bring novel treatments to patients worldwide.
